News-Medical.Net October 16, 2024
Dr. Chinta Sidharthan

As AI technology evolves rapidly, the FDA is tackling the challenge of balancing innovation with patient safety, shaping regulations that ensure AI tools remain effective throughout their entire lifecycle.

A Special Communication published in the Journal of the American Medical Association (JAMA) examined the regulation of artificial intelligence (AI) in healthcare by the United States (U.S.) Food and Drug Administration (FDA). It also explored AI’s potential in clinical research, development of medical products, and patient care while highlighting the key areas to address as regulations are adapted for some of AI’s distinctive challenges in biomedicine and healthcare.

Background

Advances in AI have immense potential for transforming biomedicine and healthcare. Expectations from AI often exceed those from previous medical technologies such...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Regulations, Safety, Technology
Related Articles:
Opinion: STAT+: The biggest challenge facing the FDA’s new Rare Disease Innovation Hub
STAT+: For this cancer-focused digital health startup, an FDA rejection meant the end of the road
Legacy medical devices keep regulators up at night
How the FDA sees its role vis-à-vis AI in healthcare
FDA, Health Canada give sneak peek into future AI regs

Share This Article